What types of diseases can the new anti-cancer drug Platinib (Pujihua) treat?

Pralsetinib is a new anti-cancer targeted drug that has attracted much attention in recent years. It is a selective RET inhibitor. RETGene fusions or mutations are found in a variety of malignant tumors and are important factors driving the proliferation and spread of cancer cells. Platinib inhibits tumor growth and metastasis by highly selectively inhibiting RET kinase activity, thereby cutting off the signaling pathways of tumor cells. Compared with traditional chemotherapy, Platinib is more targeted and has fewer side effects, bringing new treatment options to some cancer patients.

In the field of lung cancer, platinib is widely used to treat RET gene fusion-positive non-small cell lung cancer (NSCLC). Such patients often do not respond well to conventional chemotherapy or immunotherapy, and platinib can significantly improve the response rate and prolong progression-free survival. Research shows that platinib can also show good efficacy in patients who have received previous treatment, providing new hope for this group of people.

In addition to lung cancer, platinib is also used to treat thyroid cancer associated with RET mutations or fusions. Especially for patients with medullary thyroid cancer (MTC) and partially differentiated thyroid cancer (DTC) who are ineffective in radioactive iodine therapy, Platinib shows a high effective rate. Its targeting effect can help patients control their disease and delay tumor progression, which is especially significant for patients who are ineffective or resistant to traditional treatments.

In addition, platinib also has potential application value in other rareRET fusion-driven solid tumors. Clinical trial results suggest that it may also benefit some patients with pancreatic cancer, cholangiocarcinoma, and other rare tumors. Although related indications are still under research and expansion, platinib, as an important representative of RET targeted therapy, has gradually become an important part of precision medicine, providing more personalized treatment options for patients with different cancer types.

Reference link:https://www.drugs.com